News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Announces Presentation Of New MARINE And ANCHOR Post-Hoc Analyses At National Lipid Association Annual Scientific Sessions Showing Vascepa® Significantly Reduced Apolipoprotein C-III Levels



5/2/2014 9:44:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDMINSTER, N.J., and DUBLIN, Ireland, May 2, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa® (icosapent ethyl) capsules significantly reduced apolipoprotein C-III (ApoC-III) levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride (TG) metabolism.i This research is being presented today by Christie M. Ballantyne, M.D. from Baylor College of Medicine as part of a peer-reviewed poster session at the National Lipid Association Annual Scientific Sessions in Orlando, Florida.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES